Clinical Trials Logo

Alzheimer's Disease clinical trials

View clinical trials related to Alzheimer's Disease.

Filter by:

NCT ID: NCT02916056 Terminated - Alzheimer's Disease Clinical Trials

2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)

Start date: December 2016
Phase: Phase 3
Study type: Interventional

This is an open-label extension study in patients with mild Alzheimer's disease who have completed participation in the azeliragon Phase 3 (STEADFAST) trial. Patients will receive azeliragon 5 mg/day for up to 2 years.

NCT ID: NCT02912936 Recruiting - Alzheimer's Disease Clinical Trials

A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease

MINT-01
Start date: September 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to determine safety, tolerability, and pharmacokinetics/dynamics of a ketogenic dietary supplement containing medium chain triglycerides (MCTs) in patients with Alzheimer disease (AD). Novel imaging and laboratory biomarkers in response to this intervention will also be explored.

NCT ID: NCT02912169 Withdrawn - Alzheimer's Disease Clinical Trials

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Alzheimer's Disease

Start date: November 1, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The intent of this clinical study is to answer the questions: 1) Is the proposed treatment safe and 2) Is treatment effective in improving the disease pathology of patients with Alzheimer's Disease and clinical outcomes?

NCT ID: NCT02910739 Completed - Alzheimer's Disease Clinical Trials

An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)

Start date: October 11, 2016
Phase: Phase 1
Study type: Interventional

This study consists of Part I and an optional Part II. The purpose of Part I is to compare the plasma pharmacokinetics of verubecestat (MK-8931) following administration of a single oral dose of 40 mg MK-8931 to participants with moderate hepatic insufficiency (HI) to that of healthy matched controls. An interim safety and pharmacokinetic analysis on the basis of Part I will be performed in order to support the decision to continue with the optional Part II. If a decision to continue with Part II is made, participants with mild HI will be enrolled to receive a single oral dose of 40mg MK-8931. If any healthy participants from Part I do not meet the matching criteria for Part II additional healthy participants will be enrolled.

NCT ID: NCT02910102 Completed - Alzheimer's Disease Clinical Trials

Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia

Start date: October 2016
Phase: Phase 2
Study type: Interventional

This study seeks to evaluate the effect of intepirdine (RVT-101) on gait and balance in patients with Alzheimer's Disease, Dementia with Lewy Bodies or Parkinson's Disease Dementia.

NCT ID: NCT02908815 Recruiting - Alzheimer's Disease Clinical Trials

Investigating the Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) as a Treatment for Alzheimer's Disease

Start date: November 2016
Phase: N/A
Study type: Interventional

The main objective of this study is to investigate the effects of repetitive Transcranial Magnetic Stimulation (rTMS) treatment on patients with probable early or moderate Alzheimer's disease.

NCT ID: NCT02907567 Completed - Alzheimer's Disease Clinical Trials

Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease

Start date: September 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease to evaluate the safety and tolerability of oral CT1812, administered for 28 days. This trial may include up to 8 qualified investigator sites in Australia.

NCT ID: NCT02899091 Active, not recruiting - Alzheimer's Disease Clinical Trials

Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease

Start date: September 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate safety and potential therapeutic effect of intraveneously administered CB-AC-02 in patients with Alzheimer's Disease.

NCT ID: NCT02884492 Terminated - Alzheimer's Disease Clinical Trials

Imaging Tau in Alzheimer's Disease and Normal Aging

Start date: July 2016
Phase: Phase 2
Study type: Interventional

This study is being done to learn about tau tangles in Alzheimer's disease. A type of PET scan is used to measure the abnormal accumulation of protein called tau in the brain. These are thought to be involved in Alzheimer's disease. The investigators will also perform brain MRI and to tests to measure the participant's memory and thinking.

NCT ID: NCT02880956 Completed - Alzheimer's Disease Clinical Trials

A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease

Start date: January 26, 2017
Phase: Phase 2
Study type: Interventional

This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).